Nitroglycerin
- 1 lab in 1 country
- 64 trials, none about aging, 26 with no results posted
- Funders: National Heart, Lung, and Blood Institute and 2 more
- Human trial1
Outcomes
1Arterial diameter
upin humans1
1 study
Arterial diameter
upin humans1
Nitroglycerin increases arterial diameter in humans (0.29-0.35 mm).
“In the PA, compared with zero, NTG significantly increased diameter in all groups”
Human trialsublingualpopliteal artery0.8 mg
Journal of applied physiology (Bethesda, Md. : 1985)Jun 30, 2023
Trials
0 about aging, of 64Approved
Sep 30, 1981Discontinued
Oct 6, 1981Discontinued
Oct 19, 1981Discontinued
Jan 5, 1982Discontinued
Jan 19, 1983Discontinued
FDA Nitrolingual, Nitrolingual Pumpspray
Oct 31, 1985Angina Pectoris, Coronary Artery Disease
All 14Fewer
Dec 10, 1985Angina Pectoris, Coronary Artery Disease
FDA Nitroglycerin IN Dextrose 5%
Dec 29, 1989Angina Pectoris, Heart Failure, Hypertension, Acute Myocardial Infarction, intraoperative hypotension
May 1, 2000Angina Pectoris, Coronary Artery Disease
Nov 2, 2006
Jun 21, 2011DiscontinuedRECTIV ® (nitroglycerin) Ointment 0.4% is indicated for the treatment of moderate to severe pain associated with chronic anal fissure.…
Jun 8, 2016Discontinued
Discontinued
Discontinued
Repurposing
Phase 4Results posted3 trials
Phase 3Completed1 trial
Phase 3Completed1 trial
Phase 3Completed1 trial
Phase 3Completed2 trials
Phase 3Results posted1 trial
All 30Fewer
Phase 3Completed2 trials
Phase 4Status unknown2 trials
Phase 3Completed1 trial
Phase 4Recruiting1 trial
Phase 4Results posted1 trial
Phase 3Completed1 trial
Phase 4Status unknown1 trial
Phase 4Completed2 trials
Phase 3Completed1 trial
Phase 4Status unknown4 trials
Phase 2Completed2 trials
Phase 2Completed1 trial
Chronic obstructive pulmonary disease
Phase 2/3Recruiting1 trial
Phase 2Results posted3 trials
Phase 2Terminated1 trial
Phase 2Terminated1 trial
Phase 2Status unknown1 trial
Phase 2Completed1 trial
Phase 2Status unknown1 trial
Phase 2Completed3 trials
Early phase 1Status unknown1 trial
Early phase 1Status unknown1 trial
Phase 1Completed1 trial
Phase 1Results posted1 trial
In trials
Stable Angina
Phase 4Status unknown3 trials
Chronic renal insufficiency
Phase 4Results posted1 trial
Raynaud Disease
Phase 3Completed4 trials
Diffuse Scleroderma
Phase 3Completed3 trials
Fissure in Ano
Phase 3Results posted3 trials
Spasm
Phase 3Results posted2 trials
All 7Fewer
Hyperlipidemias
Phase 3Results posted1 trial
Stopped
NCT03304496SuspendedCoronary artery disease
The sample was not completed.
NCT01210378TerminatedNon small cell lung carcinoma
Accrual stopped
NCT01811693TerminatedStroke
The funding period for the study has ended.
Trial sponsors
Shaanxi Buchang Pharmaceutical
Company1 trialPhase 4300 people
Company4 trialsPhase 3331 people
Company1 trialPhase 3248 people
Company2 trialsPhase 2272 people
Company1 trialPhase 265 people
Company1 trialPhase 250 people
Company1 trialPhase 249 people
Company1 trialPhase 1106 people
Funding
1 grant since 2018National Institute on AgingUS$1.1m